Stage III serous ovarian adenocarcinomas

ABSTRACT: The clinical outcome for patients with ovarian cancer is difficult to predict. However, the use of biomarkers as additional prognostic factors may improve the outcome for these patients. In order to find novel candidate biomarkers, differences in gene expressions were analyzed in 54 stage III serous ovarian adenocarcinomas with oligonucleotide microarrays containing 27,000 unique probes. The microarray data was verified with quantitative real-time polymerase chain reaction for the genes TACC1, MUC5B and PRAME. With a hierarchical cluster analysis we detected a sub-group including 60% of the survivors. The gene expressions in tumours from patients in this sub-group of survivors were compared to the remaining tumours, and 204 genes were found to be differently expressed. We conclude that the

ORGANISM(S): Homo sapiens

SUBMITTER: Karolina Partheen 

PROVIDER: E-GEOD-12418 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress